Kisqali and Dermatitis - a phase IV clinical study of FDA data

Summary:

Dermatitis is reported as a side effect among people who take Kisqali (ribociclib succinate), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Letrozole, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Dermatitis when taking Kisqali. It is created by eHealthMe based on reports of 25,037 people who have side effects when taking Kisqali from the FDA, and is updated regularly.

What is Kisqali?

Kisqali has active ingredients of ribociclib succinate. eHealthMe is studying from 25,050 Kisqali users. Check the latest studies of Kisqali.

What is Dermatitis?

Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it) is found to be associated with 1,540 drugs and 1,232 conditions by eHealthMe. Check the latest studies of Dermatitis.

On Aug, 12, 2026

25,037 people reported to have side effects when taking Kisqali.
Among them, 69 people (0.28%) have Dermatitis.

Among these 69 people:

How long have people been on Kisqali when they have Dermatitis? *

What is the gender of people who have Dermatitis when taking Kisqali? *

female: 100 %
male: 0.0 %

What is the age of people who have Dermatitis when taking Kisqali? *

What are other drugs people take besides Kisqali? *

What are other side effects people have besides Dermatitis? *

Nausea (feeling of having an urge to vomit): 31 people, 44.93%
Malaise (a feeling of general discomfort or uneasiness): 28 people, 40.58%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 23 people, 33.33%
Diarrhea: 23 people, 33.33%
Fever: 22 people, 31.88%
Dizziness: 21 people, 30.43%
Joint Pain: 21 people, 30.43%
Rashes (redness): 20 people, 28.99%
General Physical Health Deterioration (weak health status): 20 people, 28.99%
Abdominal Pain: 19 people, 27.54%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 50 people, 72.46%
Breast Cancer: 20 people, 28.99%
High Blood Pressure: 6 people, 8.70%
Gastritis (inflammation of stomach): 5 people, 7.25%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 4.35%
High Blood Cholesterol: 3 people, 4.35%
Bone Disorder: 2 people, 2.90%
Metastases To Lymph Nodes (cancer spreads to lymph node): 1 person, 1.45%
Bone Cancer Metastatic: 1 person, 1.45%

* Approximation only. Some reports may have incomplete information.

Do you take Kisqali and have Dermatitis?

- Check whether Dermatitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kisqali:

Kisqali (25,050 reports)

Dermatitis treatments and more:

Dermatitis (30,577 reports)

Browse all side effects of Kisqali:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatitis:

Dermatitis (1,540 drugs)

Browse all the conditions that are associated with Dermatitis:

Dermatitis (1,232 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ribociclib succinate (the active ingredients of Kisqali) and Kisqali (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.